In 2018, Mezquita et al. studied 466 patients with advanced non-small cell lung cancer receiving PD-1/PD-L1 inhibitors and were the first to develop the LIPI to investigate the relationship between poor outcomes of PD-1/PD-L1 inhibitors and the LIPI score. Here, CD274 is linked to non-small cell lung carcinoma.